TABLE 1.
Correlations among MLST types, PCR ribotypes, and antimicrobial susceptibility patterns of C. difficile isolates
| Antimicrobial agenta | Total no. (%) of isolatesb (n = 411) | MLST type (no. [%] of nonsusceptible isolates) |
Analysis resultsc |
PCR ribotype (no. [%] of nonsusceptible isolates) |
Analysis resultsc |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST2 (n = 46) | ST3 (n = 67) | ST37 (n = 68) | ST54 (n = 53) | Other STs (n = 177) | χ2 | P value | 001 (n = 59) | 012 (n = 55) | 017 (n = 68) | Others (n = 229) | χ2 | P value | ||
| Fusidic acid | 290 (70.6) | 36 (78.3) | 42 (62.7) | 55 (80.9) | 46 (86.8) | 111 (62.7) | 18.77 | 0.001 | 37 (62.7) | 48 (87.3) | 55 (80.9) | 150 (65.5) | 15.42 | 0.001 |
| Ciprofloxacin | 334 (81.3) | 36 (78.3) | 61 (91.0) | 54 (79.4) | 50 (94.3) | 133 (75.1) | 14.95 | 0.005 | 53 (89.8) | 52 (94.5) | 54 (79.4) | 175 (76.4) | 12.90 | 0.005 |
| PIP-TAZ | 5 (1.2) | 1 (2.2) | 0 | 0 | 0 | 4 (2.3) | 4.26 | 0.372 | 0 | 0 | 0 | 5 (2.2) | 4.01 | 0.26 |
| Metronidazole | 64 (15.6) | 9 (19.6) | 10 (14.9) | 5 (7.4) | 4 (7.6) | 36 (20.3) | 9.73 | 0.045 | 10 (17.0) | 6 (10.9) | 5 (7.4) | 43 (18.8) | 6.28 | 0.099 |
| Rifampin | 38 (9.3) | 6 (13.0) | 1 (1.5) | 8 (11.8) | 11 (20.8) | 12 (6.8) | 15.75 | 0.003 | 1 (1.7) | 11 (20.0) | 8 (11.8) | 18 (7.9) | 12.63 | 0.006 |
| Moxifloxacin | 104 (25.3) | 9 (19.6) | 25 (37.3) | 18 (26.5) | 2 (3.8) | 50 (28.3) | 19.77 | 0.001 | 22 (37.3) | 2 (3.6) | 18 (23.4) | 62 (27.1) | 18.57 | <0.001 |
| Gatifloxacin | 133 (32.4) | 10 (21.7) | 29 (43.3) | 36 (52.9) | 1 (1.9) | 57 (32.2) | 41.67 | <0.001 | 23 (39.0) | 3 (5.5) | 36 (50.7) | 71 (31.0) | 32.72 | <0.001 |
| Vancomycin | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 | 0 | 0 | 0 | — | — |
| Clindamycin | 257 (62.5) | 30 (65.2) | 53 (79.1) | 37 (54.4) | 35 (66.0) | 102 (57.6) | 12.01 | 0.017 | 48 (81.4) | 35 (63.6) | 37 (52.1) | 137 (59.8) | 11.58 | 0.009 |
| Levofloxacin | 308 (74.9) | 36 (78.3) | 58 (86.6) | 52 (76.5) | 37 (69.8) | 125 (70.6) | 7.68 | 0.104 | 52 (88.1) | 39 (70.9) | 52 (73.2) | 165 (72.1) | 7.05 | 0.07 |
| Tetracycline | 149 (36.3) | 12 (26.1) | 21 (31.3) | 24 (35.3) | 35 (66.0) | 57 (32.2) | 24.38 | <0.001 | 21 (35.6) | 35 (63.6) | 24 (35.3) | 69 (30.1) | 21.60 | <0.001 |
| Erythromycin | 266 (64.7) | 20 (43.5) | 50 (74.6) | 57 (83.8) | 36 (67.9) | 103 (58.2) | 26.38 | <0.001 | 46 (78.0) | 38 (69.1) | 57 (83.1) | 125 (54.6) | 26.16 | <0.001 |
| MDR | 306 (74.5) | 30 (65.2) | 53 (79.1) | 57 (83.8) | 47 (88.7) | 119 (67.2) | 16.46 | 0.003 | 49 (83.1) | 48 (87.3) | 60 (83.8) | 149 (48.7) | 24.45 | <0.001 |
a
PIP-TAZ: piperacillin-tazobactam; MDR: multidrug resistant.
b
Of 411 isolates, 6 (1.5%), 14 (3.4%), 1 (0.2%), 1 (0.2%), 1 (0.2%), 6 (1.5%), 8 (1.9%), 0 (0%), 8 (1.9%), 12 (2.9%), 9 (2.2%), and 15 (3.6%) nontoxigenic isolates of nonsusceptible fusidic acid, ciprofloxacin, PIP-TAZ, metronidazole, rifampin, moxifloxacin, gatifloxacin, vancomycin, clindamycin, levofloxacin, tetracycline, and erythromycin were found, respectively. A total of 11 (2.7%) nontoxigenic MDR isolates were found.
c
—, data not calculated.